

## About Albert:

Prof. Albert Wiegman, born in Amsterdam, the Netherlands, became a paediatrician and member of the staff at the Amsterdam University Medical Centres in 1991. In 1993, he completed his sub-specialisation in paediatric cardiology. In that year, the paediatric-lipid department came under his care. He started his research into the treatment of familial hypercholesterolemia in children, in close cooperation with prof John JP Kastelein, head of the Department of vascular medicine.

He brought the research to completion in his thesis: 'Paediatric implications of heterozygous Familial Hypercholesterolemia'. In 2020, he was appointed associate professor and principal investigator.



He is a member of the Scientific Advisory Committee of FH Europe Foundation and played a key role in the EU Commission Submission of the FH Paediatric Screening Best Practice, which was successfully accepted in 2020. This achievement laid the foundation for all the policy and advocacy work for paediatric screening of FH and early detection at FH Europe Foundation. Since 2024, he has also served as a trustee of the FH Europe Foundation.

His scientific impact is measured also in publications, 188 Publications with 18,377 reads and 11,210 citations.

His deep medical expertise and unwavering commitment to improving the lives of young patients make him a perfect judge for evaluating health-focused creative initiatives. Prof. Wiegman's ability to translate complex medical knowledge into actionable public health strategies, combined with his compassionate approach to patient care, ensures that he brings both scientific rigor and heartfelt dedication to his role as a judge.



## GALAXY FORCES UNITED: For HoFH Awareness Day

#Unite4HoFH

www.fhef.org/hofh-awareness-day



